2023 World Conference on Lung Cancer (Posters)-EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients

EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients - PDF(Abstract)

Pdf Summary

This document is a summary of a presentation titled "Hypofractionated Radiotherapy for Elderly Lung Cancer Patients" at the WCLC 2023 conference. The presentation aimed to evaluate the treatment outcomes of hypofractionated radiotherapy (HFX) for elderly lung cancer patients. <br /><br />The study analyzed fifty-two patients who were treated with HFX using IMRT from 2019 to 2022. The patients received HFX to the primary, recurrent or progressive tumor, with a median dose of 45 Gy delivered in a median of 13 fractions. The fraction sizes ranged from 2.5 to 6 Gy. The median total biologically effective dose was 56.3 Gy.<br /><br />The results showed that the overall survival of the patients was a median of 13.2 months. The 1-year rates of local relapse-free survival, regional relapse-free survival, and distant relapse-free survival were 89.6%, 80.0%, and 95.3% respectively. Seven patients (13.5%) experienced symptomatic radiation pneumonitis (RP) with grade 2, but no patients experienced RP of grade 3.<br /><br />In conclusion, the study found that elderly lung cancer patients treated with HFX achieved acceptable disease control rates and experienced minimal side effects in the form of RP. However, the researchers highlighted the need for further follow-up duration and patients to validate these findings. The keywords associated with this presentation were lung cancer, radiation dose hypofractionation, and elderly.

Asset Subtitle

Jeong Won Lee

Meta Tag

Speaker Jeong Won Lee

Topic Metastatic NSCLC: Local Therapies - Effects

Keywords

lung cancer

radiation dose hypofractionation

elderly

Hypofractionated Radiotherapy

WCLC 2023 conference

treatment outcomes

IMRT

biologically effective dose

overall survival

radiation pneumonitis